NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-066-2015-0-US-03 BIODOSIMETRY ANALYSIS US National Stage 15/769,718 Abandoned
NICHD E-062-2015-0-US-03 Codon-optimized Reduced-size ATP7A Complementary DNA And Uses for Treatment of Copper Transport Disorders US National Stage 15/769,294 10988778 Issued PDF
NINDS E-143-2002-1-US-77 Zenapax (Humanized Antibody Against The IL-2 Receptor Alpha Chain) As A Novel Treatment For Multiple Sclerosis US CON 15/956,458 Abandoned
NCI E-021-2001-0-US-15 Chromosome 3p21.3 Genes Are Tumor Suppressors US CON 15/955,310 Abandoned
NHLBI E-249-2006-3-US-09 Expanded Claims For Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure And Coronary Artery And Myocardial Protection US CON 15/954,555 10687942 Issued PDF
NLM E-107-2010-2-US-19 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 15/952,352 Abandoned
NCI E-208-2015-0-KR-06 Thalidomide Analogs and Methods of Use KR National Stage 10-2018-7012347 Pending
NCI E-001-2016-0-SA-14 Anti-CD30 Chimeric Antigen Receptors SA ORD 518391355 Abandoned
NCI E-001-2016-0-JP-09 ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS JP National Stage 2018-518999 Abandoned
NCI E-184-2016-1-US-03 Targeted Combination Therapy US National Stage 16/604,790 Pending
NCI E-184-2016-1-JP-10 Targeted Combination Therapy JP National Stage 2019-555879 Pending
NCI E-184-2016-1-EP-08 Targeted Combination Therapy EP National Stage 18783979.0 Pending
NCI E-184-2016-1-CN-07 Targeted Combination Therapy CN National Stage 201880038534.X Pending
NCI E-184-2016-1-CA-06 Targeted Combination Therapy CA National Stage 3059882 Pending
NCI E-184-2016-1-BR-05 Targeted Combination Therapy BR National Stage BR112019021476-3 Pending
NCI E-184-2016-1-AU-04 Targeted Combination Therapy AU National Stage 2018251788 Pending
NCI E-184-2016-1-PCT-02 Targeted Combination Therapy PCT PCT PCT/US2018/027080 Expired
NCI E-184-2016-1-IL-09 Targeted Combination Therapy IL National Stage 269986 Pending
NIDDK E-742-2013-0-US-07 A3 ADENOSINE RECEPTOR AGONISTS US DIV 15/949,701 10577368 Issued PDF
NCI E-282-2016-2-US-32 Methods For Pre-conditioning Patients For Cell Therapy US CON 15/950,042 Pending
NCI E-001-2016-0-US-11 ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS US National Stage 15/766,948 10815301 Issued PDF
CC E-026-2015-0-EP-04 Repeat Biopsy System And Method EP National Stage 2016759872 Pending
NCI E-001-2016-0-IL-12 Anti-CD30 Chimeric Antigen Receptors IL ORD 258527 Issued
NCI E-174-2018-2-US-02 CAS9 Modified TILS For Treatment Of Gastrointestinal Cancer US National Stage 15/947,688 10912797 Issued PDF
NICHD E-093-2017-0-PCT-02 ISOTROPIC GENERALIZED DIFFUSION TENSOR MRI PCT PCT PCT/US2018/026584 Expired
NCI E-001-2016-0-BR-04 ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS BR National Stage BR112018006995-7 Abandoned
NCI E-035-2017-0-HK-10 STAT3 INHIBITOR FORMULATION HK National Stage 62020006657.4 Issued
NCI E-035-2017-0-MX-15 STAT3 INHIBITOR FORMULATION MX National Stage MX/a/2019/011913 Issued
NCI E-035-2017-0-NL-23 STAT3 INHIBITOR FORMULATION NL EP 18720845.9 Issued
NCI E-035-2017-0-IT-22 STAT3 INHIBITOR FORMULATION IT EP 18720845.9 Issued
NCI E-035-2017-0-GB-21 STAT3 INHIBITOR FORMULATION GB EP 18720845.9 Issued
NCI E-035-2017-0-SE-25 STAT3 INHIBITOR FORMULATION SE EP 18720845.9 Issued
NCI E-035-2017-0-PL-24 STAT3 INHIBITOR FORMULATION PL EP 18720845.9 Issued
NCI E-035-2017-0-ES-19 STAT3 INHIBITOR FORMULATION ES EP 18720845.9 Issued
NCI E-035-2017-0-EP-09 STAT3 INHIBITOR FORMULATION EP National Stage 18720845.9 Issued
NCI E-035-2017-0-DE-18 STAT3 INHIBITOR FORMULATION DE EP 18720845.9 Issued
NCI E-035-2017-0-FR-20 STAT3 INHIBITOR FORMULATION FR EP 18720845.9 Issued
NCI E-035-2017-0-JP-13 STAT3 INHIBITOR FORMULATION JP National Stage 2019-555108 Issued
NCI E-035-2017-0-IN-12 STAT3 INHIBITOR FORMULATION IN National Stage 201917044212 Issued
NCI E-035-2017-0-AU-03 STAT3 INHIBITOR FORMULATION AU National Stage 2018248303 Issued
NCI E-035-2017-0-BR-04 STAT3 INHIBITOR FORMULATION BR National Stage BR1120190209859 Issued
NCI E-035-2017-0-PCT-02 STAT3 INHIBITOR FORMULATION PCT PCT PCT/US2018/026228 Expired
NCI E-035-2017-0-CA-05 STAT3 INHIBITOR FORMULATION CA National Stage 3058973 Issued
NCI E-035-2017-0-CO-08 STAT3 INHIBITOR FORMULATION CO National Stage NC2019/012386 Issued
NCI E-035-2017-0-CL-06 STAT3 INHIBITOR FORMULATION CL National Stage 02843-2019 Issued
NCI E-035-2017-0-PE-16 STAT3 INHIBITOR FORMULATION PE National Stage 1997-2019 Issued
NCI E-035-2017-0-KR-14 STAT3 INHIBITOR FORMULATION KR National Stage 10-2019-7032793 Issued
NIAID E-137-2018-2-EA-07 Peptide-based Vaccines, Methods Of Manufacturing, And Uses Thereof For Inducing An Immune Response EA National Stage 201992367 Issued
NIAID E-137-2018-2-IL-09 Peptide-based Vaccines, Methods Of Manufacturing, And Uses Thereof For Inducing An Immune Response IL National Stage 269830 Issued
NIAID E-137-2018-2-PCT-01 Peptide-based Vaccines, Methods Of Manufacturing, And Uses Thereof For Inducing An Immune Response PCT PCT COMB PCT/US2018/026145 Expired